Newron Pharmaceuticals SpA (SW:NWRN) — Stock Price
Newron Pharmaceuticals SpA (SW:NWRN) is currently trading at CHF11.90 CHF, down 2.62% today. Over the past 52 weeks, shares have ranged between CHF7.01 and CHF30.40. This page tracks Newron Pharmaceuticals SpA's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Newron Pharmaceuticals SpA (NWRN) market capitalisation.
Newron Pharmaceuticals SpA (NWRN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Newron Pharmaceuticals SpA's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Newron Pharmaceuticals SpA Income Statement — Revenue, Profit & Earnings by Year
Newron Pharmaceuticals SpA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CHF19.13 Million | CHF51.39 Million | CHF9.06 Million | CHF6.09 Million | CHF5.76 Million |
| Cost of Revenue | CHF2.10 Million | CHF892.00K | CHF471.00K | CHF443.00K | CHF117.00K |
| Gross Profit | CHF19.13 Million | CHF51.39 Million | CHF9.06 Million | CHF6.09 Million | CHF5.76 Million |
| Research & Development | CHF15.16 Million | CHF13.64 Million | CHF13.15 Million | CHF12.05 Million | CHF10.76 Million |
| SG&A | CHF4.76 Million | CHF7.38 Million | CHF3.98 Million | CHF3.54 Million | CHF3.49 Million |
| Total Operating Expenses | CHF23.81 Million | CHF25.22 Million | CHF20.69 Million | CHF19.40 Million | CHF18.12 Million |
| Operating Income | CHF-4.70 Million | CHF26.17 Million | CHF-11.63 Million | CHF-13.30 Million | CHF-12.36 Million |
| EBITDA | CHF-4.55 Million | CHF25.94 Million | CHF-11.83 Million | CHF-13.32 Million | CHF-11.92 Million |
| EBIT | CHF-4.73 Million | CHF25.75 Million | CHF-12.03 Million | CHF-13.53 Million | CHF-11.97 Million |
| Interest Expense | CHF4.43 Million | CHF4.35 Million | CHF4.17 Million | CHF4.36 Million | CHF2.92 Million |
| Income Before Tax | CHF-12.35 Million | CHF21.39 Million | CHF-16.20 Million | CHF-17.47 Million | CHF-14.88 Million |
| Income Tax Expense | CHF885.00K | CHF5.55 Million | CHF24.00K | CHF21.00K | CHF17.00K |
| Net Income | CHF-13.33 Million | CHF15.84 Million | CHF-16.22 Million | CHF-17.49 Million | CHF-14.90 Million |
Newron Pharmaceuticals SpA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Newron Pharmaceuticals SpA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CHF40.02 Million | CHF63.91 Million | CHF25.87 Million | CHF37.20 Million | CHF50.49 Million |
| Total Current Assets | CHF38.05 Million | CHF61.10 Million | CHF19.65 Million | CHF28.49 Million | CHF39.43 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CHF16.68 Million | CHF2.89 Million | CHF6.26 Million | CHF9.35 Million | CHF9.57 Million |
| Net Receivables | CHF6.16 Million | CHF42.42 Million | CHF2.53 Million | CHF1.94 Million | CHF1.31 Million |
| Inventory | — | — | CHF-508.00K | CHF1.00 | — |
| Property, Plant & Equipment | CHF736.00K | CHF834.00K | CHF405.00K | CHF527.00K | CHF577.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CHF51.15 Million | CHF62.45 Million | CHF55.77 Million | CHF51.23 Million | CHF47.38 Million |
| Total Current Liabilities | CHF50.09 Million | CHF23.51 Million | CHF28.93 Million | CHF5.04 Million | CHF3.65 Million |
| Long-term Debt | CHF0.00 | CHF36.24 Million | CHF25.75 Million | CHF45.16 Million | CHF42.54 Million |
| Net Debt | CHF25.96 Million | CHF43.54 Million | CHF42.08 Million | CHF32.24 Million | CHF18.06 Million |
| Total Stockholder Equity | CHF-11.13 Million | CHF1.46 Million | CHF-29.91 Million | CHF-14.03 Million | CHF3.11 Million |
| Retained Earnings | CHF-18.25 Million | CHF10.69 Million | CHF-21.40 Million | CHF-22.80 Million | CHF-20.12 Million |
Newron Pharmaceuticals SpA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Newron Pharmaceuticals SpA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CHF32.56 Million | CHF-17.61 Million | CHF-10.14 Million | CHF-11.09 Million | CHF-11.45 Million |
| Capital Expenditures | CHF47.30K | CHF13.00K | CHF11.00K | CHF18.00K | CHF20.00K |
| Free Cash Flow | CHF32.51 Million | CHF-17.63 Million | CHF-10.15 Million | CHF-11.11 Million | CHF-11.46 Million |
| Investing Cash Flow | CHF-13.75 Million | CHF3.16 Million | CHF3.25 Million | CHF-317.00K | CHF8.42 Million |
| Financing Cash Flow | CHF-13.52 Million | CHF15.05 Million | CHF-192.00K | CHF-186.00K | CHF14.83 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CHF212.00K | CHF256.00K | CHF197.00K | CHF480.00K | CHF762.00K |
| Depreciation | CHF173.12K | CHF192.00K | CHF201.00K | CHF202.00K | CHF209.00K |
| Change in Cash | CHF5.19 Million | CHF595.00K | CHF-7.09 Million | CHF-11.60 Million | CHF11.81 Million |
Newron Pharmaceuticals SpA Earnings History — EPS Actual vs. Analyst Estimates
Track Newron Pharmaceuticals SpA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | — | -0.08 | — |
| Sep 30, 2025 | — | -0.12 | — |
| Sep 16, 2025 | 0.00 | -0.50 | +100.00% |
| Apr 17, 2025 | — | — | — |
| Mar 31, 2025 | 1.12 | -0.49 | +328.57% |
| Sep 15, 2022 | 0.00 | -0.44 | +100.00% |
| Mar 01, 2018 | -0.41 | -1.00 | +59.00% |
| Sep 14, 2017 | 0.09 | -0.35 | +125.71% |